Last updated: February 28, 2026
What is the Therapeutic Indication and Market Potential?
NDC 71288-0106 corresponds to Xtandi (enzalutamide), a non-steroidal anti-androgen indicated primarily for prostate cancer treatment. It is approved for multiple indications:
- Metastatic castration-resistant prostate cancer (mCRPC)
- High-risk non-metastatic castration-resistant prostate cancer (nmCRPC)
- Non-metastatic hormone-sensitive prostate cancer (mHSPC)
Market potential hinges on prostate cancer incidence, competitive landscape, and regulatory approvals.
Market Size and Growth Drivers
- Prostate cancer prevalence: Approximately 268,000 new cases annually in the U.S. (SEER data, 2022)
- Market growth rate: Estimated CAGR of 8-10% over next five years (EvaluatePharma, 2023)
Major players include Xtandi (P-fit pharm), Zytiga (Johnson & Johnson), and other emerging agents targeting similar pathways.
Regulatory and Patent Status
- Patent expiration: Expected around 2028-2030, depending on jurisdictions
- Orphan drug status: Granted in certain indications, extending exclusivity periods
Competitive Landscape
| Drug Name |
Mechanism |
Regulatory Status |
Indications |
Market Share (2022) |
| Xtandi |
Androgen receptor inhibitor |
Approved worldwide |
mCRPC, nmCRPC, mHSPC |
65% |
| Zytiga |
Androgen synthesis inhibitor |
Approved |
mCRPC, nmCRPC, mHSPC |
25% |
| Erleada |
Androgen receptor antagonist |
Approved |
nmCRPC |
5% |
Xtandi leads with a dominant market share in prostate cancer therapeutics.
Pricing and Revenue Projections
Current Pricing
- U.S. average wholesale price (AWP): ~$9,600 per month for a typical dosage (Medicare data, 2022)
- Per annum cost: ~$115,200
Revenue Projections
Assuming:
- Market penetration: 70% of eligible prostate cancer patients
- Patient base growth: 8-10% CAGR
- Pricing stability: No significant drops before patent expiry
- 2023 sales estimate: $3.2 billion (EvaluatePharma, 2023)
Price Sensitivity and Reimbursement Trends
- Insurance coverage favors branded drugs, limiting discounts
- Ongoing biosimilar development may exert downward pressure post-patent expiry
Price Trajectory Outlook
| Year |
Estimated Wholesale Price |
Rationale |
| 2023 |
$9,600/month |
Current market price, steady reimbursement |
| 2025 |
$9,600/month |
Expected stability before patent expiry |
| 2028 |
Potential decline to $7,500/month |
Entry of biosimilars, patent expiry |
Risks and Opportunities
- Patent challenges: Delays or invalidations could accelerate price declines
- Line extension: Additional indications may sustain revenue streams
- Regulatory approvals: Expanded uses may boost market share and prices
Summary
NDC 71288-0106 (Xtandi) remains the leading agent in prostate cancer, commanding high prices with stable revenue outlooks through 2027. Price declines are anticipated post-patent expiry, with biosimilar competition likely to reduce costs. Continued market expansion depends on new indications and regulatory approvals.
Key Takeaways
- The drug maintains dominant market share with current wholesale prices around $9,600/month.
- Revenue projections for 2023 hover near $3.2 billion, with steady growth driven by increasing prostate cancer prevalence.
- Patent expiration around 2028-2030 is expected to induce pricing pressures, especially from biosimilar entrants.
- The competitive landscape is consolidated but evolving, with Zytiga and Erleada as primary competitors.
- Market expansion hinges on approval of additional indications and uptake in non-metastatic settings.
FAQs
1. What factors influence the pricing of enzalutamide (Xtandi)?
Pricing depends on manufacturing costs, reimbursement policies, market competition, patent protections, and clinical demand.
2. How soon could biosimilars impact Xtandi’s market share?
Likely post-2028, coinciding with patent expiry, although biosimilar development timelines vary.
3. Are there upcoming regulatory decisions that could alter the market?
Yes; approvals for new indications or line extensions could sustain or grow revenue streams.
4. How does the pricing of Xtandi compare internationally?
International prices are generally lower due to pricing regulations, reimbursement negotiations, and market differences.
5. What is the potential for generic(enalutamide) entry?
Patents covering enzalutamide must expire for generics to enter, with significant impact expected after 2028.
References
[1] SEER Cancer Statistics Review, 2022. National Cancer Institute.
[2] EvaluatePharma, 2023. World Preview: Outlook to 2028.
[3] Centers for Medicare & Medicaid Services, 2022. Average Wholesale Price Data.
